Patients’ preferences for preventive osteoporosis drug treatment EW de Bekker-Grob ML Essink-Bot WJ Meerding HAP Pols BW Koes EW Steyerberg Dept. Public Health, Dept. Internal Medicine, and Dept. General Practice, Erasmus MC Rotterdam, the Netherlands [email protected]
16
Embed
Patients’ preferences for preventive osteoporosis drug treatment
Patients’ preferences for preventive osteoporosis drug treatment. EW de Bekker-Grob ML Essink-Bot WJ Meerding HAP Pols BW Koes EW Steyerberg Dept. Public Health, Dept. Internal Medicine, and Dept. General Practice, Erasmus MC Rotterdam, the Netherlands [email protected]. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Patients’ preferences for preventive osteoporosis drug treatment
EW de Bekker-GrobML Essink-BotWJ MeerdingHAP PolsBW KoesEW Steyerberg
Dept. Public Health, Dept. Internal Medicine, and Dept. General Practice, Erasmus MC Rotterdam, the Netherlands
tablet once a month):tablet once a week -0.31 <0.001* -0.45 -0.17injection every four months -0.21 0.027* -0.41 -0.02injection once a month -0.44 <0.001* -0.64 -0.25
Number of observations 5,589 (117 respondents x 16 choices x 3 options per choice, minus 27 missing values), Pseudo R2 = 0.1847, log pseudolikelihood = -1668.7
RESULTS: TRADE-OFFS
WTP for total
treatment (€)
Constant (no drug treatment) 32.7 847Drug administration (base level
tablet once a month):tablet once a week 8.2 212injection every four months 5.7 147injection once a month 11.7 304
Number of observations 5,589 (117 patients (i.e. 58 low-risk + 59 high-risk patients) x 16 choices x 3 options per choice, minus 27 missing values), Pseudo R2 = 0.190, log pseudolikelihood = -1659
CONCLUSIONS
1. Women exhibited a very positive attitude towards preventive osteoporosis drug treatment
2. Important message for policy decision-making on introduction of active osteoporosis case finding at large scale (in addition to cost-effectiveness considerations)
3. This study demonstrates feasibility of DCE in older patients
We would like to thank the Netherlands Organization for Health Research and Development (ZonMw) for funding the research.